Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Transl Med ; 11(485)2019 03 27.
Article in English | MEDLINE | ID: mdl-30918111

ABSTRACT

Tau inclusions are a shared feature of many neurodegenerative diseases, among them frontotemporal dementia caused by tau mutations. Treatment approaches for these conditions include targeting posttranslational modifications of tau proteins, maintaining a steady-state amount of tau, and preventing its tendency to aggregate. We discovered a new regulatory pathway for tau degradation that operates through the farnesylated protein, Rhes, a GTPase in the Ras family. Here, we show that treatment with the farnesyltransferase inhibitor lonafarnib reduced Rhes and decreased brain atrophy, tau inclusions, tau sumoylation, and tau ubiquitination in the rTg4510 mouse model of tauopathy. In addition, lonafarnib treatment attenuated behavioral abnormalities in rTg4510 mice and reduced microgliosis in mouse brain. Direct reduction of Rhes in the rTg4510 mouse by siRNA reproduced the results observed with lonafarnib treatment. The mechanism of lonafarnib action mediated by Rhes to reduce tau pathology was shown to operate through activation of lysosomes. We finally showed in mouse brain and in human induced pluripotent stem cell-derived neurons a normal developmental increase in Rhes that was initially suppressed by tau mutations. The known safety of lonafarnib revealed in human clinical trials for cancer suggests that this drug could be repurposed for treating tauopathies.


Subject(s)
Farnesyltranstransferase/antagonists & inhibitors , Tauopathies/drug therapy , Tauopathies/metabolism , Animals , Brain/drug effects , Brain/metabolism , Brain/pathology , Disease Models, Animal , Enzyme Inhibitors/pharmacology , Female , GTP-Binding Proteins/antagonists & inhibitors , GTP-Binding Proteins/genetics , GTP-Binding Proteins/metabolism , Humans , Induced Pluripotent Stem Cells/drug effects , Induced Pluripotent Stem Cells/metabolism , Lysosomes/drug effects , Lysosomes/metabolism , Male , Mice , Mice, Transgenic , Mutation , Neurons/drug effects , Neurons/metabolism , Piperidines/pharmacology , Proteolysis/drug effects , Pyridines/pharmacology , RNA, Small Interfering/genetics , Tauopathies/pathology , Translational Research, Biomedical , tau Proteins/genetics , tau Proteins/metabolism
2.
Tissue Eng Part A ; 22(7-8): 597-609, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26956095

ABSTRACT

Soft tissue defects are relatively common, yet currently used reconstructive treatments have varying success rates, and serious potential complications such as unpredictable volume loss and reabsorption. Human adipose-derived stem cells (ASCs), isolated from liposuction aspirate have great potential for use in soft tissue regeneration, especially when combined with a supportive scaffold. To design scaffolds that promote differentiation of these cells down an adipogenic lineage, we characterized changes in the surrounding extracellular environment during adipogenic differentiation. We found expression changes in both extracellular matrix proteins, including increases in expression of collagen-IV and vitronectin, as well as changes in the integrin expression profile, with an increase in expression of integrins such as αVß5 and α1ß1. These integrins are known to specifically interact with vitronectin and collagen-IV, respectively, through binding to an Arg-Gly-Asp (RGD) sequence. When three different short RGD-containing peptides were incorporated into three-dimensional (3D) hydrogel cultures, it was found that an RGD-containing peptide derived from vitronectin provided strong initial attachment, maintained the desired morphology, and created optimal conditions for in vitro 3D adipogenic differentiation of ASCs. These results describe a simple, nontoxic encapsulating scaffold, capable of supporting the survival and desired differentiation of ASCs for the treatment of soft tissue defects.


Subject(s)
Adipogenesis/drug effects , Adipose Tissue/cytology , Biomimetic Materials/pharmacology , Hydrogel, Polyethylene Glycol Dimethacrylate/pharmacology , Stem Cells/cytology , Tissue Scaffolds/chemistry , Vitronectin/pharmacology , Amino Acid Sequence , Cell Adhesion/drug effects , Cells, Immobilized/cytology , Cells, Immobilized/drug effects , Extracellular Matrix/drug effects , Extracellular Matrix/metabolism , Humans , Integrins/metabolism , Oligopeptides/chemistry , Oligopeptides/pharmacology , Polyethylene Glycols/chemistry , Stem Cells/drug effects
3.
Neuron ; 83(1): 69-86, 2014 Jul 02.
Article in English | MEDLINE | ID: mdl-24991955

ABSTRACT

Neural stem cells have been adopted to model a wide range of neuropsychiatric conditions in vitro. However, how well such models correspond to in vivo brain has not been evaluated in an unbiased, comprehensive manner. We used transcriptomic analyses to compare in vitro systems to developing human fetal brain and observed strong conservation of in vivo gene expression and network architecture in differentiating primary human neural progenitor cells (phNPCs). Conserved modules are enriched in genes associated with ASD, supporting the utility of phNPCs for studying neuropsychiatric disease. We also developed and validated a machine learning approach called CoNTExT that identifies the developmental maturity and regional identity of in vitro models. We observed strong differences between in vitro models, including hiPSC-derived neural progenitors from multiple laboratories. This work provides a systems biology framework for evaluating in vitro systems and supports their value in studying the molecular mechanisms of human neurodevelopmental disease.


Subject(s)
Artificial Intelligence , Cerebral Cortex/embryology , Embryonic Stem Cells/physiology , Gene Regulatory Networks/genetics , Models, Neurological , Neural Stem Cells/physiology , Artificial Intelligence/trends , Cells, Cultured , Cerebral Cortex/cytology , Female , Humans , Male
4.
Stem Cells Transl Med ; 2(5): 384-93, 2013 May.
Article in English | MEDLINE | ID: mdl-23599499

ABSTRACT

Controlling the differentiation of human pluripotent stem cells is the goal of many laboratories, both to study normal human development and to generate cells for transplantation. One important cell type under investigation is the retinal pigmented epithelium (RPE). Age-related macular degeneration (AMD), the leading cause of blindness in the Western world, is caused by dysfunction and death of the RPE. Currently, RPE derived from human embryonic stem cells are in clinical trials for the treatment of AMD. Although protocols to generate RPE from human pluripotent stem cells have become more efficient since the first report in 2004, they are still time-consuming and relatively inefficient. We have found that the addition of defined factors at specific times leads to conversion of approximately 80% of the cells to an RPE phenotype in only 14 days. This protocol should be useful for rapidly generating RPE for transplantation as well as for studying RPE development in vitro.


Subject(s)
Cell Differentiation , Pluripotent Stem Cells/cytology , Retinal Pigment Epithelium/cytology , Activins/pharmacology , Cell Differentiation/drug effects , Cell Differentiation/genetics , Cell Line , Cell Lineage/drug effects , Cell Proliferation/drug effects , Cells, Cultured , Gene Expression Regulation/drug effects , Humans , Niacinamide/pharmacology , Pluripotent Stem Cells/drug effects , Pluripotent Stem Cells/metabolism , Pyrroles/pharmacology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Retinal Pigment Epithelium/drug effects , Retinal Pigment Epithelium/metabolism , Time Factors , Vasoactive Intestinal Peptide/pharmacology , Visual Fields/drug effects
5.
Stem Cells ; 27(10): 2427-34, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19658190

ABSTRACT

Human induced pluripotent stem cells (iPSCs) have great promise for cellular therapy, but it is unclear if they have the same potential as human embryonic stem cells (hESCs) to differentiate into specialized cell types. Ocular cells such as the retinal pigmented epithelium (RPE) are of particular interest because they could be used to treat degenerative eye diseases, including age-related macular degeneration and retinitis pigmentosa. We show here that iPSCs generated using Oct4, Sox2, Nanog, and Lin28 can spontaneously differentiate into RPE cells, which can then be isolated and cultured to form highly differentiated RPE monolayers. RPE derived from iPSCs (iPS-RPE) were analyzed with respect to gene expression, protein expression, and rod outer segment phagocytosis, and compared with cultured fetal human RPE (fRPE) and RPE derived from hESCs (hESC-RPE). iPS-RPE expression of marker mRNAs was quantitatively similar to that of fRPE and hESC-RPE, and marker proteins were appropriately expressed and localized in polarized monolayers. Levels of rod outer segment phagocytosis by iPS-RPE, fRPE, and hESC-RPE were likewise similar and dependent on integrin alpha v beta 5. This work shows that iPSCs can differentiate into functional RPE that are quantitatively similar to fRPE and hESC-RPE and further supports the finding that iPSCs are similar to hESCs in their differentiation potential.


Subject(s)
Cell Differentiation/physiology , Pluripotent Stem Cells/cytology , Pluripotent Stem Cells/metabolism , Retinal Pigment Epithelium/cytology , Retinal Pigment Epithelium/metabolism , Biomarkers/analysis , Biomarkers/metabolism , Brain Tissue Transplantation/methods , Cell Differentiation/drug effects , Cell Line , Cell Polarity/physiology , Cell Proliferation , Homeodomain Proteins/metabolism , Homeodomain Proteins/pharmacology , Humans , Integrin alphaV/metabolism , Nanog Homeobox Protein , Nerve Tissue Proteins/analysis , Nerve Tissue Proteins/metabolism , Octamer Transcription Factor-3/metabolism , Octamer Transcription Factor-3/pharmacology , Phagocytosis/physiology , Phenotype , Pluripotent Stem Cells/drug effects , RNA, Messenger/analysis , RNA, Messenger/metabolism , Regeneration/drug effects , Regeneration/physiology , Retinal Diseases/therapy , Retinal Rod Photoreceptor Cells/cytology , Retinal Rod Photoreceptor Cells/metabolism , SOXB1 Transcription Factors/metabolism , SOXB1 Transcription Factors/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...